Trial Profile
A Placebo-Controlled, Four-Period Crossover, Single Ascending Oral Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of the CCR9 Receptor Antagonist GSK1605786 in Japanese Healthy Male Subject
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Dec 2023
Price :
$35
*
At a glance
- Drugs Vercirnon (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 12 Jun 2012 New trial record